33 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod https://www.zacks.com/stock/news/2195315/pharma-stock-roundup-abbv-to-buy-cere-jnj-s-2024-view-lly-nvs-get-fda-nod?cid=CS-ZC-FT-analyst_blog|stock_roundup-2195315 Dec 08, 2023 - AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
Top Analyst Reports for Johnson & Johnson, T-Mobile & Caterpillar https://www.zacks.com/commentary/2193470/top-analyst-reports-for-johnson-johnson-t-mobile-caterpillar?cid=CS-ZC-FT-research_daily-2193470 Dec 05, 2023 - Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), T-Mobile US, Inc. (TMUS) and Caterpillar Inc. (CAT).
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca https://www.zacks.com/stock/news/2193151/lilly-lly-gets-second-fda-nod-for-lymphoma-drug-jaypirca?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193151 Dec 04, 2023 - Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.

Pages: 1234

<<<Page 4